###### Strengths and limitations of this study

-   This review is the first to comprehensively summarise the various prognostic models that have been produced to identify complications, severity and risk of mortality in patients with severe malaria.

-   The review covers prognostic models produced worldwide and for all the various malaria species.

-   The review reduced the risk of bias by using an independent review process for the screening of potential articles and the extraction of data.

-   Considering the wide variety of statistical methods used to generate and validate these models, there is the risk of heterogeneity in interpretation of the results.

-   The search was carried out in only one language which could potentially exclude some relevant studies published in different languages.

Introduction {#s1}
============

Malaria is a disease caused by infection with a protozoan parasite of the genus *Plasmodium*. The most relevant of these species is *Plasmodium falciparum* as it causes most deaths from the disease.[@R1] Another species of relevance is *Plasmodium vivax* which is predominantly found in Asia and has a wider distribution.[@R2] Malaria infection can result in severe disease and is associated with a high mortality. In about 108 countries where the transmission of the disease still occurs, an estimated 435 000 people died in 2017.[@R3]

The incidence of malaria cases has decreased by 41% worldwide in the last 10 years, with about 17 countries in Latin America and the Middle East reporting no new cases of malaria over this period.[@R3] There are, however, concerns that the fight against malaria might be slowed down by an overemphasis on prevention over treatment.[@R6]

Treatment and clinical management of malaria is made difficult due to potential evolution of simple infections into life-threatening severe disease; the multiorgan affection of severe disease; the dilemma of when to admit to intensive care units (ICUs) considering limited resources and the occurrence of concomitant sepsis infection with malaria.[@R7] Some of these issues can be addressed with the help of guidelines; scores or models that could help clinicians predict the occurrence of severe disease and complications in order to act appropriately.

We therefore conducted this review to systematically assess the various predictive models or scores available to guide clinicians in the management of severe malaria, whether these models have been validated and if there is any evidence that they are being successfully used in the clinical setting.

Methods {#s2}
=======

Institutional review board approval and informed consent were not required for this systematic review. We reported our findings according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines ([online supplementary appendix 1](#SP1){ref-type="supplementary-material"}).
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Search strategy and selection criteria {#s2-1}
--------------------------------------

We searched MEDLINE, CINAHL and Global Health databases using a tailored search strategy ([online supplementary appendix 2](#SP1){ref-type="supplementary-material"}) to identify all the relevant titles and abstracts of studies (randomised control trials, cohort, cross-sectional and case--control studies) published in English from inception of the database up to the 4 September 2019, that reported predictive/prognostic scores or models that could be used in the management of malaria. These included:

1.  Scores/models that predicted the severity of disease as this could guide clinicians' decisions to admit for intensive care management or the use of parenteral treatment.

2.  Scores/models that predicted the potential development of complications (including coma or cerebral malaria; shock; acidosis; severe anaemia; acute kidney injury; hypoglycaemia; respiratory failure and sepsis).

3.  Scores/models that predicted mortality in patients with malaria infection.

The main keywords in the search strategy included: 'prognostic model/score', 'predictive model/score' and 'predictive value of tests' coupled with 'malaria', 'plasmodium', 'anti-malarials', 'malaria falciparum', 'malaria vivax' and 'clinical malaria'. We further canvassed the references of eligible papers to identify similar papers for review.

We excluded any duplicate studies, editorials, systematic reviews, case studies, conference abstracts, unpublished studies and expert commentaries. For studies with more than one publication of findings, we selected the most recent publication.

We also excluded studies which contained models or scores that were aimed at the diagnosis of malaria as we intend to limit the scope of the review to only models that could be used to predict severity, mortality or risk of complications---that could guide clinicians in their management options. Studies that used animal models to predict disease severity were also excluded.

Two independent reviewers (TN and BST) screened the titles and abstracts for compliance to the aforementioned inclusion and exclusion criteria and any conflicts were settled by mutual agreement. Articles considered to have data relevant to the topic were assessed in detail and the references cited in these publications were searched to identify further publications.

Data extraction {#s2-2}
---------------

Data extraction sheets which were prepared prior to screening were used by the two independent reviewers to obtain the following details for inclusion into the final review: last name of first author; date of publication; period of patient recruitment and/or follow-up; country of study; sample size; age group; type of predictive model; name of model; method of internal validation (calibration and discrimination); diagnostic properties of model and evidence of external validation or use in clinical settings.

Definitions {#s2-3}
-----------

By prognostic/predictive model, we mean a statistical tool which uses at least two points (or variables) of patient data to predict a specific clinical outcome.[@R9] Prognostic models applied in clinical settings are usually used at the discretion of physicians for accurate future predictions based on characteristics gathered in the present.[@R9] The information found in prognostic models is usually specific to the patients' characteristics rather than the disease or treatment and includes: prediction of chance or the duration of survival; classification of patients into risk groups; and prediction of clinical events related to the treatment the patient is receiving.[@R11]

For models that used the area under the curve (AUC) or c-statistic to assess discrimination, the following classification was used: 0.90--1---excellent; 0.80--0.90---good; 0.70--0.80---fair; 0.60--0.70---poor and 0.50--0.60---very poor discriminative properties.[@R12]

Data synthesis and analysis {#s2-4}
---------------------------

We assessed and discussed the selected studies qualitatively to describe the diagnostic properties of the models proposed in the study, their intended purpose and evidence of use of the model in other clinical settings.

We further divided the models into various categories: models used to predict a potential complication of severe malaria; models used to predict mortality as an outcome and models used to predict severity of malaria infection.

Assessment of risk of bias and applicability {#s2-5}
--------------------------------------------

The risk of bias and applicability of the models in the various studies were assessed by the two independent reviewers using the Prediction model Risk Of Bias Assessment Tool (PROBAST)[@R13] ([online supplementary appendix 3](#SP1){ref-type="supplementary-material"}). Any disagreements were handled by mutual agreement.

Patient and public involvement {#s2-6}
------------------------------

Patients and the public were not involved in the design and conduction of this review.

Results {#s3}
=======

A total of 564 articles were identified by the electronic search of the databases. The titles and abstracts of these articles were screened to retain 59 articles for full text review. These were then evaluated according to the inclusion criteria and 24 articles were identified describing 27 models/scores of interests; after eliminating 23 irrelevant articles, 9 articles which used only one variable to predict an outcome and two articles describing models in other languages ([figure 1](#F1){ref-type="fig"}).

![Flowchart showing reasons for exclusion of various studies from the review.](bmjopen-2019-030793f01){#F1}

Two of the articles described models predicting complications of malaria[@R8]; 15 described original models predicting mortality in severe malaria[@R16]; 3 described models predicting mortality in different contexts but adapted and validated to predict mortality in malaria[@R31]; and 4 articles described models predicting severity of the disease.[@R34] One of the articles described three models to predict mortality paediatric severe malaria,[@R31] while another described two models to predict mortality in adult severe malaria.[@R24] The rest of the articles described one model each.

Using the PROBAST to assess risk of bias and applicability, none of the studies had a low risk of bias while six studies were not found to be applicable in real-life settings[@R15] ([online supplementary appendix 3](#SP1){ref-type="supplementary-material"}).

The general characteristics of the studies included in the review are summarised in [tables 1--4](#T1 T2 T3 T4){ref-type="table"}.

###### 

Summary of articles with models predicting complications in severe malaria

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  N                                             Study                 Year   Period of participant recruitment   Country                                     Type of study              Sample size   Statistics used       Name of model   Method internal\   Age profiles                                 Sex\             Outcome predicted                                                                Variables used                                                                                                                 Diagnostic properties                          External validation   Use in clinical settings
                                                                                                                                                                                                                                            of\                                                             profiles                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                            validation                                                                                                                                                                                                                                                                                                                                                            
  --------------------------------------------- --------------------- ------ ----------------------------------- ------------------------------------------- -------------------------- ------------- --------------------- --------------- ------------------ -------------------------------------------- ---------------- -------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------- --------------------- --------------------------
  **Complications of malaria severe anaemia**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  1                                             Weber *et al*[@R15]   1997   July to December 1994               Gambia                                      Cohort                     368           Logistic regression   None            None               Median age: 28 months (IQR: 14--48 months)   Females---49%    Paediatric development of severe anaemia in malaria (packed cell volume \<15%)   Pallor of conjunctiva and pallor of palms                                                                                      Sensitivity of 80% and a specificity of 85%.   None                  NE

  **Development of sepsis**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  2                                             Njim *et al*[@R8]     2018   June 2003 to May 2005               Bangladesh, India, Indonesia and Myanmart   Randomised control trial   1187          Logistic regression   None            Bootsrapping       17--87 years                                 Female---24.3%   Development of clinical sepsis in adults with severe falciparum malaria          Sex, blood urea nitrogen levels, plasma anion gap, respiratory distress, shock on admission, parasitaemia, coma and jaundice   AUC: 0.789.\                                   None                  NE
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Sensitivity---70.0%; specificity---69.4%                             
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AUC, area under the curve; NE, no evidence.

###### 

Summary of articles with models predicting mortality in paediatric severe malaria

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  N               Study                                             Year                               Period of participant recruitment   Country                                                                    Type of study                                                    Sample size                                                                       Statistics used        Name of\                                                                                                       Method internal of validation                     Age profiles                         Sex\                 Outcome predicted                                      Variables used                                                                                                                                                                                                                     Diagnostic properties                                                                                   External validation   Use in clinical settings
                                                                                                                                                                                                                                                                                                                                                                                                model                                                                                                                                                                                                 profiles                                                                                                                                                                                                                                                                                                                                                                                                                                     
  --------------- ------------------------------------------------- ---------------------------------- ----------------------------------- -------------------------------------------------------------------------- ---------------------------------------------------------------- --------------------------------------------------------------------------------- ---------------------- -------------------------------------------------------------------------------------------------------------- ------------------------------------------------- ------------------------------------ -------------------- ------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- --------------------- --------------------------
  **Mortality**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  1               Jaffar *et al*[@R21]                              1997                               1992--1994                          Gambia                                                                     Retrospective analysis of data from a randomised control trial   624                                                                               Logistic regression    None                                                                                                           None                                              1--9.5 years                         Females---49%        Mortality in paediatric cerebral malaria               Cold periphery, deep coma and hypoglycaemia                                                                                                                                                                                        Not done                                                                                                None                  NE

  2               Molyneux *et al*[@R27]                            1989                               January 1987 to June 1988           Malawi                                                                     Cohort                                                           131                                                                               Univariable analysis   Bedside prognostic index                                                                                       None                                              7 months to 10 years                 Females---55.7%      Mortality in paediatric cerebral malaria               Blood glucose, parasitaemia, WBC count, age, coma score, absent corneal reflexes, decerebration, convulsions                                                                                                                       Positive predictive value---83%, sensitivity---66%                                                      None                  NE

  3               Conroy *et al*[@R16]                              2012                               1997--2009                          Malawi                                                                     Cohort                                                           155                                                                               Logistic regression    None                                                                                                           Hosmer-Lemeshow goodness-of-fit test              8 months to 14 years                 Females---54.4%      Mortality in patients with cerebral malaria            Age, Blantyre coma score, respiratory distress, severe anaemia, angiopoietin-1, angiopoietin-2 and sTie-2\                                                                                                                         C-index of 0.79 (95% CI 0.72 to 0.84)                                                                   None                  NE
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  levels                                                                                                                                                                                                                                                                                                                                                           

  4               Krishna *et al*[@R22]                             1994                               1988--1989                          Gambia                                                                     Cohort study                                                     115                                                                               Logistic regression    None                                                                                                           Wald statistic and ROC analysis                   18 months to 12 years                NC                   Mortality in paediatric severe malaria                 Coma score, whole blood lactate/glucose ratio, TNF level                                                                                                                                                                           Wald statistic: coma score (4.5), lactate/glucose ratio (8.36), TNF level (6.5)                         None                  NE

  5               Marsh *et al*[@R23]                               1995                               May 1989 to November 1991           Kenya                                                                      Cohort                                                           1844                                                                              Logistic regression    None                                                                                                           None                                              Mean: 26 months                      NC                   Mortality in children with severe malaria              Impaired consciousness, respiratory distress, hypoglycemia, and jaundice                                                                                                                                                           Predicted 92.2% of deaths                                                                               None                  NE

  6               Newton *et al*[@R28]                              2005                               January 2001 to December 2003       Malawi, Kenya and Ghana                                                    Cohort                                                           14 605                                                                            Linear regression      None                                                                                                           AUROC                                             Mean age: 32--36 months              Females---53%--55%   Mortality in paediatric severe falciparum malaria      Deep breathing, Blantyre Coma Score, inability to sit, weight-for-age Z score, hypoglycaemia, base excess and lactate concentration                                                                                                c-statistic 0.83--0.88 in the three sites: Blantyre (0.88), Kilifi (0.87) and Kumasi (0.83)             None                  NE

  7               Gérardin *et al*[@R32]                            2006                               1 October 1997 to 31 March 1999     Senegal                                                                    Cohort                                                           311                                                                               Logistic regression    PRISM (paediatric risk of mortality)\                                                                          Hosmer-Lemeshow χ^2^ test                         Median: 8 years (IQR: 5--11 years)   Females---40.5%      Mortality in children with falciparum malaria          Systolic blood pressure, temperature, mental status, heart rate, dilatation of pupils, pH, total CO~2~, PCO~2~, arterial PaO~2~, serum glucose, potassium, urea, creatinine, white blood cells, prothrombin time, platelet count   AUROC for acute malaria: 0.89 (95% CI 0.85 to 0.92) and 0.86 (95% CI 0.81 to 0.90) for severe malaria   Yes                   NE
                                                                                                                                                                                                                                                                                                                                                                                                AUC: 0.92[@R40]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  8               Helbok *et al*[@R20]                              2009                               December 2000 to May 2005           Gambia, Malawi, Kenya, Ghana, and Gabon                                    Cohort                                                           23 890                                                                            Logistic regression    LODS (Lambaréné Organ Dysfunction Score)                                                                       Internal validation using Bonferroni correction   Mean: 30--38 months                  Females---41%--47%   Mortality in children with severe falciparum malaria   Coma, prostration and deep breathing                                                                                                                                                                                               AUROC: 0.80 (0.79 to 0.82)                                                                              Yes                   NE

  9               von Seidlein *et al*[@R30]                        2012                               2005--2010                          Gambia, Mozambique, Nigeria, Rwanda, Kenya, DRC, Tanzania, Ghana, Uganda   Retrospective analysis                                           5426                                                                              Logistic regression    None                                                                                                           ROC analysis                                      Median: 2.8 years (1.7, 4.3)         NC                   Mortality in paediatric severe falciparum malaria      Base deficit, coma, convulsions, BUN and chronic illness                                                                                                                                                                           AUROC: 0.85 (95% CI 0.83 to 0.87)                                                                       None                  NE

  10              Conroy *et al*[@R31]                              2015                               NC                                  Uganda                                                                     Cohort                                                           1589                                                                              Logistic regression    SICK (Signs of Inflammation in Children that Kill) ^38^---AUC\*: 0.887 (sensitivity 84.1% specificity 82.2%)   Hosmer-Lemeshow goodness-of-fit                   NC                                   Females---54.3%      Mortality in malaria                                   Altered consciousness, temperature, heart rate, respiratory rate, systolic blood pressure, capillary refill time and age                                                                                                           AUROC: 0.846                                                                                            Yes                   NE

                  LODS[@R57]                                        Hosmer-Lemeshow goodness-of- fit   NC                                  Females---54.3%                                                            Mortality in malaria                                             Prostration, coma (BCS) and deep breathing                                        AUROC: 0.898           Yes                                                                                                            NE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

                  PEDIA[@R39]---AUC\*: 0.93 (95% CI 0.92 to 0.94)   Hosmer-Lemeshow goodness-of- fit   NC                                  Females---54.3%                                                            Mortality in malaria                                             Kwashiokor†, jaundice, subcostal indrawing, prostration (±seizures) and wasting   AUROC: 0.896           Yes                                                                                                            NE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Diagnostic properties of original model.

†Not used in present model.

AUROC, area under the receiver operating curve; BCS, Blantyre coma score; BUN, blood urea nitrogen; DRC, Democratic Republic of the Congo; NC, not clear; NE, no evidence; TNF, tissue necrotic factor; WBC, white blood cells.

###### 

Summary of articles with models predicting mortality in adult severe malaria

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  N               Study                                Year       Period of participant recruitment   Country                                             Type of study                                          Sample size                                                                                                      Statistics used                                                                                                                        Name of model                                                                Method internal of validation                                                           Age profiles            Sex\              Outcome predicted                                                             Variables used                                                                                                                                      Diagnostic properties                                                                                               External validation   Use in clinical settings
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      profiles                                                                                                                                                                                                                                                                                                                                                                                      
  --------------- ------------------------------------ ---------- ----------------------------------- --------------------------------------------------- ------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------- --------------------------------------------------------------------------------------- ----------------------- ----------------- ----------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- --------------------- --------------------------
  **Mortality**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  1               Wilairatana and Looareesuwan[@R41]   1995       July 1991 to\                       Thailand                                            Cohort                                                 72                                                                                                               Validation of APACHE II model (Original APACHE II score use clinical judgement and physiological relationships to assign weightings)   APACHE II score[@R58]                                                        ROC analysis                                                                            Mean age: 29.9          Females---33.3%   Mortality in adult patients with cerebral falciparum malaria                  MAP, temperature, heart rate, respiratory rate, arterial pH, PaO~2~, haematocrit, WBC count, creatinine, sodium, potassium and Glasgow coma score   Predicted mortality with 95.8% accuracy                                                                             None                  NE
                                                                  May 1993                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  2               Dondorp *et al*[@R17]                2004       NC                                  Vietnam                                             Cohort                                                 268                                                                                                              Logistic regression                                                                                                                    None                                                                         Hosmer-Lemeshow goodness-of-fit test                                                    15--79 years            Females---19%     Mortality in adults with severe falciparum malaria                            Plasma lactate, plasma strong anion gap and plasma creatinine                                                                                       AUROC: 0.81                                                                                                         None                  NE

  3               Mishra *et al*[@R24]                 2007       NC                                  India                                               Cohort                                                 212                                                                                                              Linear regression                                                                                                                      MSA (malaria score for adults)                                               Not done                                                                                NC                      NC                Mortality in adults with severe malaria                                       severe anaemia, acute renal failure, respiratory distress, cerebral malaria                                                                         Sensitivity: 89.9%, specificity: 70.6%, positive predictive value: 94.1% with cut-off of 5/10                       Yes[@R43]             NE

                  MPS (malaria prediction score)       Not done   NC                                  NC                                                  Mortality in severe malaria                            Age, serum creatinine level, haemoglobin level, cerebral malaria, presence of a pregnancy, use of a ventilator   NE                                                                                                                                     Yes[@R43]                                                                    NE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  4               Hanson *et al*[@R18]                 2010       June 2003 to May 2005               Bangladesh, India, Indonesia and Myanmar            Retrospective analysis of a randomised control trial   789                                                                                                              Logistic regression                                                                                                                    CAM (coma acidosis malaria) score                                            Hosmer-Lemeshow goodness-of-fit                                                         NC                      NC                Mortality in adults with severe malaria                                       Coma and acidosis (base deficit                                                                                                                     AUROC: 0.81 (95% CI 0.77 to 0.84)                                                                                   Yes[@R59]             NE

  5               Mohapatra and Das[@R26]              2009       January 200 to December 2004        India                                               Cohort study                                           2089                                                                                                             Logistic regression                                                                                                                    MSS (Malaria severity score)                                                 Hosmer-Lemeshow goodness-of-fit (internal validation by splitting data---2089 vs 509)   18--71 years            Female---34.6%    Mortality in adult patients with severe falciparum malaria                    Neurological, renal, haematological, hepatic, respiratory, cardiovascular, and metabolic organ systems                                              AUROC: 0.9                                                                                                          None                  NE

  6               Newton *et al*[@R29]                 2013       1986--2002                          Thailand                                            Retrospective analysis                                 988                                                                                                              Logistic regression                                                                                                                    MPI (malaria prognostic index)                                               ROC curve analysis and internal validation by data splitting                            15--74 years            Females---43%     Mortality in adult severe falciparum malaria                                  Glasgow coma scale, parasitaemia, plasma lactate, serum bilirubin, pigmented parasites and treatment with ACT                                       AUROC: 0.97                                                                                                         None                  NE

  7               Mohapatra *et al*[@R25]              2014       NC                                  India                                               Cohort                                                 112                                                                                                              NC                                                                                                                                     GCBRS (GCS, creatinine, respiratory rate, bilirubin and systolic BP) score   NC                                                                                      Mean: 35.8±15.1 years   Females---16.1    Mortality in severe falciparum malaria                                        Cerebral malaria, renal failure, respiratory distress, jaundice and shock                                                                           Sensitivity: 85.3%. Specificity: 95.6%                                                                              None                  NE

  8               Hanson *et al*[@R19]                 2014       1996--2013                          Bangladesh, India, Indonesia, Vietnam and Myanmar   Randomised control trials and cohort studies           1801                                                                                                             Logistic regression                                                                                                                    None                                                                         Hosmer-Lemeshow goodness-of-fit                                                         21--45                  Females---24.4    48 hours survival and survival to discharge in patients with severe malaria   Shock, oligo-anuria, dysglycaemia, respiratory rate, Glasgow Coma Score and absence of fever                                                        PPV for 48 hour-survival: 99.4% (95% CI 97.8 to 99.9). PPV for survival to discharge: 96.9% (95% CI 94.3 to 98.5)   None                  NE
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ACT, artemisinin combined therapy;AUROC, area under the receiver operating curve; NC, not clear; NE, no evidence; PPV, positive predictive value; WBC, white blood cells.

###### 

Summary of articles with models predicting severity of malaria infection

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  N                         Study                  Year   Period of participant recruitment   Country    Type of study   Sample size                               Statistics used       Name of model                               Method internal of validation   Age profiles             Sex\             Outcome predicted                                                                         Variables used                                                                                                                                                                         Diagnostic properties                                                                      External validation   Use in clinical settings
                                                                                                                                                                                                                                                                                              profiles                                                                                                                                                                                                                                                                                                                                                                                                           
  ------------------------- ---------------------- ------ ----------------------------------- ---------- --------------- ----------------------------------------- --------------------- ------------------------------------------- ------------------------------- ------------------------ ---------------- ----------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------ --------------------- --------------------------
  **Severity of disease**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  1                         Helbok *et al*[@R35]   2003   1 October\                          Thailand   Cohort          22                                        NC                    MODS (multiorgan dysfunction score)[@R44]   None                            16--41 years             Female---41.8%   Severity of disease in adult patients with uncomplicated falciparum malaria               Ten organ systems: (heart, blood vessel, blood, respiratory system, metabolism, gastrointestinal system, liver, kidney and urinary tract, immune system, and central nervous system)   None                                                                                       None                  NE
                                                          2001 to 30 January 2002                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  2                         Helbok *et al*[@R34]   2005   1 October 2001 to 30 July 2002      Thailand   Cohort          29                                        Survival analysis     MODS[@R44]                                  None                            Mean age: 27.1 (±10.6)   Female---27.6%   Severity of disease in adult patients with severe falciparum malaria                      Ten organ systems: (heart, blood vessel, blood, respiratory system, metabolism, gastrointestinal system, liver, kidney and urinary tract, immune system and central nervous system)    None                                                                                       None                  NE

  3                         Helbok *et al*[@R36]   2006   August 2003 to May 2005             Gabon      Cohort          485                                       Survival analysis     Simplified MODS[@R35]                       ROC analysis                    4--169 months            Females---49%    Severity of disease and disability in children with severe falciparum malaria infection   Ten organ systems: (heart, blood vessel, blood, respiratory system, metabolism, gastrointestinal system, liver, kidney and urinary tract, immune system, and central nervous system)   AUC to predict prolonged disease (\>48 hours unable to walk): 0.92 (95% CI 0.89 to 0.95)   None                  NE

  4                         Grigg *et al*[@R37]    2018   October 2012 to April 2016          Malaysia   Cohort          481 patients with *Plasmodium knowlesi*   Logistic regression   None                                        None                            33 years (IQR: 21--49)   Female---43.2%   Severity of *Plasmodium knowlesi* infection using WHO 2014 research criteria[@R45]        Age \>45, abdominal pain, shortness of breath, increased parasite count, schizont proportion \>10%, bicarbonate\<18 mmol                                                               None                                                                                       None                  NE
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AUC, area under the curve; NC, not clear; NE, no evidence; TNF, tissue necrotic factor.

Models predicting the risk of complications in malaria infection {#s3-1}
----------------------------------------------------------------

Webber *et al*[@R15] in 1997 conducted a study to predict the risk of severe anaemia (packed cell volume \<15%) in children with severe malaria in the Gambia using logistic regression analysis. This model was not internally validated, and the two predictors identified were pallor of the conjunctiva and pallor of the palms. There is no evidence from this review that the model has been externally validated and is being used in clinical settings.

In 2018, Njim *et al*[@R8] described a prognostic model for clinical use to predict the risk of sepsis development among adult patients (\>16 years old) admitted for severe falciparum malaria in Southeast Asia. They used data from South East Asian Quinine Artesunate Malaria Trial (SEQUAMAT)---a large randomised control trial (RCT) conducted to determine the benefits of intravenous artesunate over quinine treatment for severe malaria. They used a multivariable logistic regression approach with internal validation using bootstrapping to generate a prognostic model with modest discriminative abilities (AUC: 0.789) containing the following predictive variables: female sex, high blood urea nitrogen, high plasma anion gap, respiratory distress, shock on admission, high parasitaemia, coma and jaundice. The model has not been externally validated and there is no evidence of use in clinical settings.

Models predicting mortality in severe malaria {#s3-2}
---------------------------------------------

### ​Models predicting mortality in paediatric severe malaria {#s3-2-1}

Ten articles described models that predicted mortality in paediatric severe malaria.[@R16] Three articles described models which predicted mortality in paediatric patients with cerebral malaria[@R16]; two articles described models generated to assess mortality in different conditions that were validated for use in the present studies[@R31]; and five articles described original models predicting the risk of mortality in children with severe malaria.[@R20]

### ​Models predicting mortality in paediatric cerebral malaria {#s3-2-2}

Molyneux *et al*[@R27] in 1989 conducted a study among 131 comatose Malawian children with severe cerebral malaria to determine the prognostic factors for death in these patients. The authors derived a 'bedside prognostic index' with: blood glucose ≤2.2 mmol/L; parasitaemia \>106 ring forms/μL; white blood cell count \>15×10/L; age ≤3 years; coma score (modification of the Glasgow coma score)=0; absent corneal reflexes; signs of decerebration and convulsions; as predictors of mortality with each predictor assigned a score of 1. Individuals with a score ≥4 were more likely to die. This score was calculated only using univariable analysis and internal and external validation were not done.

In 1997 in Gambia, Jaffar *et al*[@R21] performed a retrospective analysis on data obtained from a randomised control trial during which artemether was compared with quinine and a monoclonal antibody against tumour necrosis factor (TNF) compared with a placebo in patients with cerebral malaria. They used these data to identify predictors of mortality in cerebral malaria using a multivariable logistic regression model. A cold periphery, a coma score of either 0 or 1 (assessed using the Blantyre coma scale measured on a scale of 0--5), and hypoglycaemia were found to be present at admission in 90% of the children who died. This model was not internally validated.

Conroy *et al*[@R16] in 2012 conducted a study among 155 children aged 8 months---14 years in Malawi to determine predictors of mortality in cerebral malaria. They used a multivariable logistic regression model containing clinical parameters and biomarkers with a modest discriminative ability (C-index of 0.79) after internal validation; which contained the following variables: age, Blantyre coma score, respiratory distress, severe anaemia, angiopoietin-1, angiopoietin-2 and sTie-2 levels. The model was not externally validated.

### ​Original models predicting mortality in paediatric severe malaria {#s3-2-3}

Krishna *et al*[@R22] in 1994 conducted a study in the Gambia to predict mortality in children aged 8 months to 14 years. They used a multivariable logistic regression model internally validated using the Wald statistic to determine that the coma score (using the Blantyre coma scale), whole blood lactate/glucose ratio and TNF level were the best predictors of death.

In 1995, Marsh *et al*[@R23] studied 1844 children in Kenya to determine predictors of life-threatening malaria (risk of death) using a multivariable logistic regression model. They determined that impaired consciousness (assessed using the Blantyre coma scale), hypoglycaemia, respiratory distress and jaundice could correctly predict 84.4% of deaths in the sample population. The model was not validated internally or externally.

In 2005, Newton *et al*[@R28] conducted a study to assess the prognostic value of measures of acid/base balance in paediatric falciparum malaria. They examined 14 605 children in Malawi (Blantyre), Kenya (Kilifi) and Ghana (Kumasi); where they determined that deep breathing, Blantyre Coma Score, inability to sit, and weight-for-age Z score were independent predictors of mortality in all the three sites. Discrimination of the model was performed by calculating the area under the receiver operating curve (AUROC). After addition of laboratory data to these models---hypoglycaemia, base excess and lactate concentrations; the c-statistics obtained were 0.88 (Blantyre), 0.87 (Kilifi) and 0.83 (Kumasi) denoting good discriminative properties of the models.

Helbok *et al*[@R20] in 2009 produced the the Lambarene Organ Dysfunction Score (LODS) which combined three variables: coma, prostration and deep breathing to generate a model using multivariable logistic regression which predicted death in African children---Banjul (Gambia), Blantyre (Malawi), Kilifi (Kenya), Kumasi (Ghana), and Lambarene and Libreville (Gabon); who were admitted for severe falciparum malaria. Each component of the model was assigned a score of 1 and a LODS of 3 at admission had a 98% specificity and 25% sensitivity in predicting death. Meanwhile a LODS ≥1 had a sensitivity of 85% and a specificity of 63%. The model had good discriminative properties with an AUC of 0.80 (95% CI 0.79 to 0.82). In 2015, Conroy *et al*[@R31] externally validated this model among 1589 Ugandan children. The model showed good discriminative properties with an AUC of 0.898.

Similarly, in 2012, von Seidlein *et al*[@R30] conducted an analysis of data from an RCT carried out in several African countries (Gambia, Mozambique, Nigeria, Rwanda, Kenya, DRC, Tanzania, Ghana and Uganda) to generate a model for predicting mortality from severe falciparum malaria using multivariable logistic regression analysis and internally validated by AUROC analysis. After analysis of data from 5426 children, base deficit, impaired consciousness (assessed using the Blantyre Coma Score), convulsions, elevated blood urea and underlying chronic illness were identified in the model to predict mortality with a good discriminative ability---AUROC: 0.85 (95% CI 0.83 to 0.87).

### ​Existing models validated for use in the prediction of mortality in severe malaria in children {#s3-2-4}

As described above, Conroy *et al*[@R31] externally validated the LODS model among 1589 Ugandan children. The authors further externally validated two other scores: the Signs of Inflammation in Children that Kill (SICK) score which was developed in India as a practical triage tool using variables related to the systemic inflammatory response syndrome, with data collected from 1099 children in 2003 admitted for any paediatric illness[@R38]; and the Paediatric Early Death Index for Africa (PEDIA) score which was developed to predict early death among 8091 children in Kenya in 2003 admitted for paediatric illnesses.[@R39] The original SICK score containing the following variables: altered consciousness, temperature, heart rate, respiratory rate, systolic blood pressure, capillary refill time and age; had good discriminative properties with an AUC of 0.887.[@R38] Externally validated against this cohort of 1589 children, the score maintained its good discriminative properties with an AUC of 0.846. Similarly, the PEDIA score which originally had excellent discriminative properties with an AUC of 0.93[@R39] had good discriminative properties (AUC: 0.896) when externally validated on the cohort of 1589 Ugandan children.[@R31] The original PEDIA score contained Kwashiorkor, jaundice, subcostal indrawing, prostration (±seizures) and wasting as variables in the model. However, kwashiorkor was not included in the validation model as it was not measured among the Ugandan children.

In 2006, Gerardin *et al*[@R32] externally validated the Paediatric Risk of Mortality (PRISM) model which was originally developed in 1988 by Pollack *et al*[@R40] to reduce the number of physiological variables required for paediatric ICU death risk assessment. The model was developed from data of 1227 patients with 105 deaths and contained 14 variables: systolic blood pressure, temperature, mental status, heart rate, dilatation of pupils, pH, total CO~2~, PCO~2~, arterial PaO~2~, serum glucose, potassium, urea, creatinine, white blood cells, prothrombin time and platelet count. The original score had excellent discriminative properties with an AUC of 0.92.[@R40] Gerardin *et al* used a cohort of 311 Senegalese children admitted with severe malaria to externally validate this model. The model showed good discriminative properties in predicting death in children with severe malaria---AUC: 0.86 (95% CI 0.81 to 0.90).[@R32]

Models predicting mortality in adult severe malaria {#s3-3}
---------------------------------------------------

There were eight articles assessing models that predicted mortality in adult severe malaria.[@R17]

In 1995, Wilairatana *et al*[@R41] used the APACHE II score (the acute physiology and chronic health evaluation system score commonly used in ICUs) based on 12 physiological variables---mean arterial pressure (MAP), temperature, heart rate, respiratory rate, arterial pH, PaO~2~, haematocrit, white blood cells (WBC) count, creatinine, sodium, potassium and Glasgow coma score to predict the risk of mortality in adult patients with cerebral malaria in Thailand. The score was able to predict mortality with a 95.8% accuracy. The original APACHE II model was produced in 1985 by Knaus *et al*,[@R42] and clinical judgement and physiological relationships were used to assign weightings for the various factors in the model.

Dondorp *et al*[@R17] in 2004 created a model using logistic regression with laboratory data form 268 patients in Vietnam to determine the risk of mortality in adult patients with severe malaria. This model had a good discriminative value with an AUROC of 0.81. The laboratory variables asscoicated with mortality in this cohort were: plasma lactate, plasma creatinine and a strong anion gap. On the other hand, in 2007, Mishra *et al*[@R24] created the malaria score for adults (MSA) and the malaria prediction score (MPS) from a cohort of 212 patients in India to predict mortality in severe malaria. The MSA was an upgrade of the malaria prognostic index (MPI) which required laboratory data and included a small proportion of children. The clinical variables included in the MSA were: severe anaemia, acute renal failure, respiratory distress and cerebral malaria and had a sensitivity of 89.9% and a specificity of 70.6%. This model was externally validated by Santos *et al*[@R43] among 59 patients with imported severe malaria in Portugal and was shown to have good discriminative properties---AUROC: 0.84; 95% CI 0.70 to 0.98.

Similarly, Hanson *et al*[@R18] produced the coma acidosis malaria (CAM) score after using a logistic regression analysis on data previously collected from the SEQUAMAT. The authors proposed the use of the presence of a coma and base deficit to calculate a five-point score to predict mortality. The score had good discriminative properties with an AUROC of 0.81 (95% CI 0.77 to 0.84). The same author used data from several cohort studies and RCTs carried out in Bangladesh, India, Indonesia, Vietnam and Myanmar to predict 48 hours survival and survival to discharge in patients with severe malaria.[@R19] The model containing the variables: shock, oligoanuria, dysglycaemia, respiratory rate, Glasgow coma score and fever could correctly predict 48-hour survival in 99.4% of the patients and survival to discharge in 96.9% of patients.

Mohapatra *et al*[@R26] in 2009 carried out a cohort study of 2089 patients in 2009, where they produced the malaria severity score (MSS) to predict mortality in adult patients with severe falciparum malaria in India. They assessed seven organ systems: neurological, renal, haematological, hepatic, respiratory, cardiovascular and metabolic organ systems; assigning a maximum score of 0--3 for each organ system. The model had excellent discriminative propertiens with an AUROC of 0.9. The authors also developed the GCRBS (Glasgow coma scale, creatinine, respiratory rate, bilirubin and systolic BP) score in 2014 as an alternative to other scores like the APACHE II score which was considered cumbersome.[@R25] The score had a sensitivity of 85.3% and a specificity of 95.6% in predicting a fatal outcome in severe malaria.

In 2013 in Thailand, Newton *et al*[@R29] conducted a retrospective analysis of 988 records with severe falciparum malaria to produce the MPI validated using ROC curve analysis and internal validation by data splitting. The MPI contained the following variables: Glasgow coma scale, parasitaemia, plasma lactate, serum bilirubin, pigmented parasites and treatment with ACT and had excellent discriminative properties with an AUROC of 0.97.

Models predicting the severity of malaria {#s3-4}
-----------------------------------------

The multiorgan dysfunction score (MODS) which is an index used in severely ill patients admitted in ICUs to determine the severity of their disease irrespective of the diagnosis.[@R34] The score evaluates ten organ systems: heart, blood vessel, blood, respiratory system, metabolism, gastrointestinal system, liver, kidney and urinary tract, immune system and central nervous system---giving a score of 1--5 for each system depending on the level of dysfunction of the system, with a minimum score of 10 and a maximum score of 50.[@R35] Helbok *et al* assessed the use of this score to predict severity in a small cohort (n=22) of adult patients with uncomplicated falciparum malaria[@R35] and in adults with severe malaria (n=29)[@R34] in Thailand. The score was not internally validated in both studies but the authors showed that higher scores were correlated with symptom severity and duration of hospitalisation. In 2006, the authors used a simplified version of the score---simplified MODS (sMODS); in a cohort of 485 children in Gabon to predict the level of severity of the disease with respect to the amout of disability the children suffered into categories: ability to walk unaided and ability to sit unaided.[@R36] The authors obtained an AUC of 0.92 (95% CI 0.89 to 0.95) in predicting inability to walk ≥48 hours for children with sMODS ≥16 and an AUC of 0.90 (95% CI 0.87 to 0.93) in predicting inability to sit unaided ([table 4](#T4){ref-type="table"}).

Grigg *et al* in 2018, used a multivariable logistic regression model to predict the severity of *Plasmodium knowlesi* malaria infection in a cohort of 481 participants in Malaysia. The authors showed that independent predictors of disease severity using the WHO 2014 research criteria[@R45] were: increasing age, abdominal pain, shortness of breath, increasing parasite count, schizont proportion \>10% and serum bicarbonate levels \<18 mmol. The model was not internally or externally validated ([table 4](#T4){ref-type="table"}).

Discussion {#s4}
==========

In this review, we report on the various prognostic models and scores produced to predict complications, mortality and severity of malaria infection. We showed that there were 2 models produced to predict the risk of developing complications from malaria infection, 12 models that predict mortality from severe malaria in children, 9 models that predict mortality from severe malaria in adults and 4 models that predict disease severity in malaria. Seventeen of these models were internally validated while only seven have been externally validated. There is no published evidence that any of these models are routinely used in clinical settings.

The models identified in this review that were used to predict mortality in children with severe malaria have similar clinical predictors. All the models had neurological dysfunction based on either the Glasgow coma score, impaired consciousness, altered mental status, convulsions, decerabration or coma as a predictor. Similarly, in adults, all the models predicting mortality also had neurological dysfuction as a predictor. Microvascular obstruction in capillaries of the brain due to direct sequestration of red blood cells infected with the malaria parasite could lead to tissue hypoxia.[@R46] The effects of this sequestration and its sequelae in the brain can be directly visualised in both adults and children as retinopathy.[@R16] This leads to varied results with increased intracranial pressure more pronounced in children than in adults.[@R46] With the increased oxygen demand associated with brain hypoxia and raised intracranial pressure, coma and brain dysfunction could therefore become an important predictor of mortality.

In children, half of the models predicting mortality had hypoglycaemia as a predictor.[@R21] Hypoglycaemia is usually implicated as a complication of severe malaria infection. This association has been said to be multifactorial.[@R49] Proposed mechanisms for this association include: increased glucose use by the malaria parasites in the red blood cells, inhibition of gluconeogenesis by the cascade of cytokines released due to infection and prolonged starvation and fasting especially in severely ill children further compounds the problem.[@R49] Considering that glucose is the primary source for organs like the brain which is likely suffering from the above highlighted effects of microvascular obstruction and sequestration; depleted glucose sources could lead to neurological dysfuction including seizures, deepening comas and hence death. As above, any factor that significantly affects neurological dysfuction could be highly predictive of mortality or disease severity in patients.

Half of the models in children predicting mortality had respiratory distress (including deep breathing and subcostal indrawing) as a predictor.[@R16] Meanwhile, six out of the nine models in adults had respiratory failure as a clinical predictor of mortality.[@R19] The incidence of respiratory distress in severe malaria is quite common as it occurs in about 40% of children with severe falciparum malaria and in 25% of adults.[@R51] It results from acute respiratory distress syndrome (ARDS); metabolic acidosis; fluid overload possibly resulting from increased inflammatory related capillary permeability and endothelial damage[@R8]; and aspiration pneumonia which could lead to sepsis[@R8]---a common association with severe malaria. The high mortality rates (up to 87% in some cases) associated with respiratory failure like in ARDS[@R52] could explain the predictive significance of respiratory distress in predicting mortality in malaria infection. Respiratory failure usually leads to hypoxia and a high probability of acute mortality in patients.

Acidosis was also a prominent predictor of mortality in most of the models predicting mortality. It was present in three of the models predicting mortality in children[@R28] and five models predicting mortality in adults.[@R17] Acidosis usually results from underlying pathologies like respiratory distress, renal failure and shock. These three variables were also common variables in the models predicting mortality in both children and adults identified in this review. Renal failure expressed in these models either as acute renal failure, oligoanuria or estimates of the kidney function using serum urea and creatinine[@R17]; is due to acute tubular necrosis that occurs in severe malaria infection as a direct result of microvascular obstruction of capillaries by infected red blood cells leading to the release of inflammatory cytokines like TNF.[@R53] Similarly, shock expressed either as a function of the systolic blood pressure or cold peripheries in three models in children[@R21] and likewise in two models in adults[@R19] could result from peripheral vasodilation which may usually occur concomitantly with sepsis and is a marker of a poor prognosis.[@R8]

From the above, factors that were predictive of disease severity and mortality seemed to be consistent among these studies. The factors that should therefore be considered by physicians when faced with a patient with malaria infection should include: neurological dysfunction (coma and seizures), acidosis, hypoglycaemia and respiratory distress ([figure 2](#F2){ref-type="fig"}). These factors seem to be highly predictive of mortality and disease severity in most of the articles that were included in the review and should therefore be included in any future studies attempting to predict these outcomes in malaria ([table 5](#T5){ref-type="table"}).

![Predictive factors of disease severity and mortality in malaria infection.](bmjopen-2019-030793f02){#F2}

###### 

Findings of review, research gaps and potential for future research

  Findings of review                                                                                                                                       Research gaps                                                                               Potential for future research                                                                             Other possible avenues
  -------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Several models available to predict various outcomes in severe malaria.                                                                                                                                                                                                                                                                                        Incorporation of produced models into artificial intelligence to help in the fast prediction of risks of adverse outcomes and suggestions of treatment and management modalities.
  Variables consistent in predicting disease severity, mortality and complications include: neurological dysfunction, respiratory distress and acidosis.   Models that take into consideration these major variables.                                  Studies with robust designs.                                                                              
  Most models have high risk of bias due to lack of use of up-to-date methods of internal validation.                                                      Models without risk of bias that use adequate statistical methods of internal validation.   Internal validation and wide external validation to help integrate models into daily clinical practice.   

We found evidence of external validation in only seven of the models identified in this study.[@R18] External validation is an important component as it determines the generalisability of the model and its potential use in different geographical regions.[@R56] As outlined above, most of the models have similar variables highlighting the fact that the predictors of complications, severity and mortality in malaria might be consistent across different settings. Emphasis could therefore be better placed in the validation of existing models and initiating their use in clinical settings to guide clinicians on prioritising patients and anticipating outcomes. Publication of the findings on the use of these models in clincal settings should also be encouraged to guide clinicians on which models work better in various settings.

After assessment of the risk of bias of the various models, 18 of the studies contained models that used variables that could be readily available and hence were applicable in real-life settings. However, all the models had a high risk of bias. This was primarily due to the lack of internal validation in several of the studies or the lack of use of up-to-date methods of validation. Caution should therefore be used when interpreting and using the results from the articles.

This review has some limitations. The search included only articles that were published in English. This could potentially lead to the exclusion of studies and models that could otherwise have been included in the review.

Conclusion {#s5}
==========

Models predicting severity and mortality of malaria infection identified in this review have similar predictors. Evidence is, however, lacking on the generalisability of most of these models due lack of external validation. Emphasis should therefore be placed on external validation of existing models and publication of the findings of their use in clinical settings to guide clinicians on management options depending on the priorities of their patients.
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